This episode is a COVID-19 podcast with a first-hand focus. Podcast host Ruairi Mackenzie discusses his experience with symptomatic COVID-19. And we also look at the data around COVID-19 risk and age and discuss the emerging problems posed by long COVID.
On this episode, the team will discuss how the SARS-CoV-2 virus affects our brain. This podcast will untangle the disparate effects involved, covering everything from a subdued sense of smell to serious brain inflammation and damage.Listen Now
In this episode, the team discuss efforts to let your brain communicate beyond the limits of your head. Whilst much of this research is still in early stages, scientists have shown how individuals can share thoughts through brain wave-based games of Tetris, and tech entrepreneurs have looked to a future where brains can be directly joined with computers. We look into these technologies’ potential to help paralysis patients and the ethical implications of a network of interconnected brains.
In this episode, the team discuss the growing movement for sustainable science. Research has a yeti-sized ecological footprint, and here we follow the tracks from ozone-destroying CFCs and energy-guzzling freezers through to a new future for science that promises to make labs eco-friendly at last.
In this episode, the team take a deep dive into the world of biohacking. Practitioners of this DIY biology have big goals: making genetic technologies available to all, bypassing government regulation of drugs and (on the fringes of the movement) achieving immortality.
In this episode, the TN team discuss three promising vaccine candidates being developed for COVID-19. We take a deep dive into the data from these vaccine trials to try and work out what successes can be celebrated and what unanswered questions still remain.
In this episode, we discuss the potential of personalized, precision approaches to change healthcare. We hear how cancer care has been one of the first areas to take advantage of patient-specific data, the risks and rewards of increased access to genomic data and how neuroscience is beginning to explore diseases of the brain at a personal level.Listen Now
In this episode, we review the evidence surrounding vagus nerve stimulation (VNS), a therapy approved for epilepsy and depression that backers now want to use to treat a host of other conditions, include autoimmune disease and heart failure. How can scientists fill in the gaps in the VNS knowledge base?
In this episode, the Technology Networks team discuss drug treatments to combat SARS-CoV-2. These drugs, like the anti-malarial hydroxychloroquine, have often been repurposed for the task, and evidence for their efficacy remains patchy. Why do researchers turn to these medications and how will the field of drug development be changed by the COVID-19 pandemic?